Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
Discrete Choice Experiment to Assess the Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Patients With Prostate Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Astellas Pharma Global Development, Inc.
- Phone Number: 800-888-7704
- Email: Astellas.registration@astellas.com
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02199
- Analysis Group, Inc.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Physician inclusion criteria
- The physician is a certified urologist or oncologist. The final selection will be adjusted to local practice.
- The physician has cared for at least ten nmHSPC patients in the past year.
- The physician has experience prescribing NHT and ADT. Patient inclusion criteria
- The patient has nmHSPC after radiotheraphy (RT) and/or radical prostatectomy (RP), defined as an adult patient with nmPC who had RT and/or RP.
Exclusion Criteria:
Physician exclusion criteria
- None Patient exclusion criteria
- The patient is castration resistant.
- The patient has metastatic PC.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Participants
Participants will include urologists or oncologists for the physician interviews and prostate cancer patients for the patient interviews and surveys.
|
No investigational drug will be administered to participants in this study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients' Preference weights for different treatment attributes
Time Frame: Up to 1 day
|
Preference data will be collected via online survey questionnaires designed using DCE method.
|
Up to 1 day
|
|
Patients' Overall Preference for a specific treatment profile (NHT +/- ADT or ADT monotherapy)
Time Frame: Up to 1 day
|
Preference data will be collected via online survey questionnaires designed using DCE method.
|
Up to 1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Medical Director, Astellas Pharma Global Development, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 9785-MA-3547
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.